Sanofi and Evotec launch drug discovery PPP
Evotec and Sanofi have launched a Public Private Partnership (PPP) aimed at partnering with academic groups in early stage drug discovery across multiple therapeutic areas.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
Entries by Thomas Gabrielczyk
Roche providing improved anti-Her2 bispecific antibody
/in News/by Thomas GabrielczykResearchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
Forbion closes Life Sciences VC Fund at 360m
/in News/by Thomas GabrielczykLife Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at 360m, 90m above its original target of 250m.
BIOSPAIN expanding
/in News/by Thomas GabrielczykMatured, diversified and willing to expand this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in […]
Minoryx bags 21.3m Series B financing
/in News/by Thomas GabrielczykBarcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another 21.3m in a Series B financing bringing its assets to a total of 50M.
PD-1+ T cells trigger pulmonary fibrosis
/in News/by Thomas GabrielczykA team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
CRISPR-gene drive safely kills mosquitos
/in News/by Thomas GabrielczykA new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology.
CHMP with new Chair 13 meds recommended
/in News/by Thomas GabrielczykThe CHMP elected Harald Enzmann as its new Chair on Friday, and recommended thirteen medicines for approval, three thereof orphan medicines.
European biotech companies enter IPO prep course
/in News/by Thomas GabrielczykEuropean stock exchange operator Euronext kicked off its fourth annual capital markets training programme for non-listed companies this time also including companies from Germany, Italy, Spain, and Switzerland.
Novo Nordisk reveals details about its R&D transformation
/in News/by Thomas GabrielczykNovo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and […]